Anavex Life Sciences Corp (AVXL)

[rx7171]

I find it highly significant that the data was a combination of the 30 and 50 mg treatment groups.
We know from the Phase 2 trial the 50 mg group did significantly better than the 30 mg group.

If the segregated data in this trial follows that of the Phase 2 the 50 mg treatment arm data will be very very strong and convincing and will become the intended standard of care.